PF-07976016 + danuglipron

PF-07976016 + danuglipron is an investigational oral combination therapy evaluated primarily for the treatment of overweight and obesity. PF-07976016 is an oral small molecule agonist of the gastric inhibitory polypeptide receptor (GIPR), while danuglipron (PF-06882961) is an oral small molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R). The combination is being studied to determine potential pharmacokinetic interactions and combined effects on weight loss. Both mechanisms are designed to modulate incretin pathways to improve glycemic control and promote weight reduction. Pfizer is the developer and sponsor of clinical trials investigating this combination. Danuglipron monotherapy development was discontinued due to safety concerns, but the combination with PF-07976016 remains under investigation in this context[1][3][4][6][8].